MA-BRIGHTCOVE
1.2.2021 15:02:08 CET | Business Wire | Press release
Brightcove Inc. (NASDAQ: BCOV), the global leader in video for business, and South by Southwest® (SXSW® ) Conference and Festivals announced today that Brightcove has been chosen as the official video partner for the all-digital SXSW Online and SXSW EDU Online events, which, for the first time, will be completely virtual and streamed to attendees around the globe on March 16–20, 2021.
Streaming an event at the scale of SXSW required the organization to ensure that its video technology platform was not only reliable but could deliver a broadcast-grade viewing experience with a high level of security. With Brightcove, SXSW will join an expanding roster of innovative, global organizations that have successfully streamed content to massive audiences on their viewing device of choice.
SXSW Online will bring together creative thinkers from all facets of the entertainment, media, and technology industries to experience a diverse combination of pre-recorded and live programming, providing up to 650 hours of content to attendees. Through Brightcove’s award-winning, highly-scalable, and flexible digital video platform, SXSW Online will span five different channels, emulating iconic SXSW stages from years past, and give attendees the unique ability to switch channels for different content in real-time, one major benefit of at-home streaming.
“This has been such a time of change and we, like the entire world, are reshaping our perspective on how we connect. Given the obstacles faced in 2020 and beyond, there has never been a more critical time to come together to address some of the most important societal issues and challenges that lie ahead,” said Roland Swenson, CEO and Co-Founder of SXSW. “We’re excited to work with Brightcove to bring everyone a seamless digital experience at SXSW Online this March. As a leader in the video industry, Brightcove will help us meet our goals while expanding the reach and capacity of SXSW’s programming.”
SXSW will use Brightcove Beacon® to enable attendees to consume content online via web browser or via Apple TV, Roku, Fire TV, Android TV, and Samsung TV. Brightcove’s over-the-top (OTT) capabilities provide a consistent, high-quality video streaming experience regardless of device or channel. Additionally, by using Brightcove’s distinct video capabilities, SXSW and festival partners can expect an unparalleled experience through:
- Utilization of Backend Analytics: SXSW will use Brightcove’s real-time data and analytics to track attendees’ content consumption to determine what they are watching and for how long in order to gain valuable insights that will help inform and optimize future programming.
- Content Security: SXSW will use Brightcove’s secure custom authentication to grant attendees access to all relevant content.
- Signature Brand Control: SXSW will use custom branding for all live and on-demand content, enabling a consistent brand experience across each event.
- Cloud Playout Technology: SXSW is the first Brightcove client to utilize Brightcove’s new full-featured Cloud Playout for a streamlined workflow, which enables content owners and organizations to quickly and seamlessly program a scheduled playout of both on-demand and live footage.
“Brightcove is honored to work with SXSW to harness the power of video and bring the SXSW community together virtually. We know firsthand that, despite the challenges of transitioning an iconic event from in-person to 100% virtual, the right technology leads to success for our customers and the audiences they serve,” said Jeff Ray, Brightcove’s CEO. “Brightcove’s technology is the most reliable, scalable, secure, and broadcast-grade, providing all SXSW attendees with an unparalleled viewing experience that’s rooted in quality and innovation.”
As part of the partnership, Brightcove will also be the sole sponsor of the Brightcove Illumination Award, a new initiative to honor a filmmaker on the rise and to celebrate the innovation and creativity of new artists. Further details on nominees and jurists will be released closer to the festival.
All conference keynotes, featured speakers, film festival screenings, and music festival showcases will be available for streaming on the SXSW Online Platform.
About SXSW Film Festival
Now in its 28th year, SXSW Film Festival brings together creatives of all stripes over nine days to experience a diverse lineup and access to thousands of SXSW Conference sessions with visionaries from all corners of the entertainment, media, and technology industries.
About SXSW
SXSW dedicates itself to helping creative people achieve their goals. Founded in 1987 in Austin, Texas, SXSW is best known for its conference and festivals that celebrate the convergence of the interactive, film, and music industries. In 2021, the event moves to a digital format. SXSW Online offers conference sessions, music showcases, film screenings, exhibitions, and a variety of networking and professional development opportunities. An essential destination for global professionals, SXSW Online 2021 will take place March 16 - March 20. For more information, please visit sxsw.com . To register for the event, please visit sxsw.com/attend .
About Brightcove
When video is done right, it can have a powerful and lasting effect. Hearts open. Minds change. Creativity thrives. Since 2004, Brightcove has been helping customers discover and experience the incredible power of video through its award-winning technology, empowering organizations in more than 70 countries across the globe to touch audiences in bold and innovative ways.
Brightcove achieves this by developing technologies once thought impossible, providing customer support without parallel or excuses, and leveraging the expertise and resources of a global infrastructure. Video is the world’s most compelling, exciting medium. Visit www.brightcove.com for more information. Video That Means Business.™
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005516/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom